Liposomes are synthetic lipid particles that have been extensively investigated over the past five decades. Despite their tremendous potential as drug delivery vehicles, there is only a handful of approved liposome-based therapeutics in the market, and the efficacy of these treatments has been noted as highly variable because of the interaction with serum proteins, drug leakage prior to the target site, and susceptibility to phagocytosis. 
Technology Overview
This proposed technology is a next-generation platform of synthetic lipid particles for antimicrobial drug delivery into chronic diabetic foot ulcers. These liposomes are similar in size to cell-derived exosomes and their lipid composition is optimized using a Design-of-Experiments (DoE) approach to reduce leakiness.
Additionally, these liposomes consist of two surface modifications: the presence of CD47 protein, and human mannose-binding-lectin (MBL) proteins. CD47 will serve as a ‘self’ signaling protein and prevent these liposomes from being phagocytosed. The human mannose-binding-lectin recognizes the peptidoglycan cell-wall components present in both Gram-positive and Gram-negative bacteria, and therefore results in targeted drug delivery.
- Longer persistence of the lipid drug-delivery particle in presence of macrophages
- Low drug leakiness from the lipid particle
- Penetration into bacterial biofilm and therefore targeted delivery of drugs to bacterial cells
- Decrease in costs associated with diabetic foot ulcer infection management
Treatment of:
- Chronic diabetic foot ulcers
- Bedsores and other cutaneous wounds
- Burn wounds
- License
- Partnering
- Research Collaboration
Patent Information:
Drug Delivery
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
Drug Delivery
Infectious Disease (including AIDS)